With unhealthy diets and sedentary lifestyles on the rise, elevated bad cholesterol poses a growing health threat, contributing to weight gain and increased risks of heart disease due to arterial blockages. While medication, exercise, and healthy living help, some patients struggle to control high cholesterol levels.

A new medication, Enlicitide, may change this. According to results from a Phase 3 clinical trial involving 2,912 adults around 63 years old, those who took Enlicitide along with their regular statin medication experienced approximately a 60% reduction in LDL (bad cholesterol) after 24 weeks. Nearly all participants were already on statins, and some were taking additional cholesterol-lowering drugs.

Besides lowering LDL cholesterol, Enlicitide also positively impacted other cholesterol-related risk factors. In contrast, participants taking a placebo showed no such improvement.

Manufactured by Merck, the company plans to seek FDA approval for Enlicitide, which could become the first pill to effectively manage cholesterol when combined with statins. However, further studies are necessary to confirm long-term cardiovascular benefits and identify potential rare side effects.

Presented at the American Heart Association Scientific Session, these encouraging results should be viewed cautiously until published in a peer-reviewed journal, as research is still underway.